Invention Grant
- Patent Title: Use of at least one biomarker for the in vitro prognosis or diagnosis of lymphoproliferative episodes associated with the Epstein-Barr virus (EBV)
-
Application No.: US14363050Application Date: 2012-12-04
-
Publication No.: US09696308B2Publication Date: 2017-07-04
- Inventor: Emmanuel Drouet , Mohammed Habib , Felix Agbalika
- Applicant: UNIVERSITE JOSEPH FOURIER
- Applicant Address: FR Grenoble
- Assignee: UNIVERSITE JOSEPH FOURIER
- Current Assignee: UNIVERSITE JOSEPH FOURIER
- Current Assignee Address: FR Grenoble
- Agency: Young & Thompson
- Priority: FR1161167 20111205
- International Application: PCT/FR2012/052790 WO 20121204
- International Announcement: WO2013/083906 WO 20130613
- Main IPC: C07K14/005
- IPC: C07K14/005 ; C12N7/00 ; G01N33/569 ; C07K16/08 ; C12Q1/70

Abstract:
A protein complex isolated from its natural medium and including the ZEBRA protein of sequence SEQ ID NO: 1, the isolated protein complex having the following properties: it is more stable than the ZEBRA protein, in particular it is more resistant to the action of the proteases than the ZEBRA protein, it is capable of specifically binding the AZ125 and AZ130 monoclonal antibodies, it is soluble in a body fluid, and in particular a body fluid selected from the group constituted by blood and serum, and to its detection process and the uses of this process for the prognosis or diagnosis of lymphoproliferative episodes associated with the EBV.
Public/Granted literature
Information query